Evidence map›Paper›PMID 29051512›Full record

ArticleScientific reports2017

Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis.

Águeda Martínez-Barriocanal, Andrea Arcas-García, Miriam Magallon-Lorenz, Aroa Ejarque-Ortíz, María Luciana Negro-Demontel, Emma Comas-Casellas, Simo Schwartz, Sunny Malhotra, Xavier Montalban, Hugo Peluffo and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Águeda Martínez-BarriocanalCIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Andrea Arcas-GarcíaCIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Miriam Magallon-LorenzCIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Aroa Ejarque-OrtízCIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
María Luciana Negro-DemontelServei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Emma Comas-CasellasCIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Simo SchwartzCIBBIM-Nanomedicine-Drug Delivery and Targeting Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Sunny MalhotraServei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Xavier MontalbanServei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Hugo PeluffoNeuroinflammation and Gene Therapy Laboratory, Institut Pasteur Montevideo, Montevideo, Uruguay.
Margarita MartínBiochemistry Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Manuel Comabella
Joan SayósCIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. joan.sayos@vhir.org.ORCID 0000-0002-4664-3461
Universitat Autònoma de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstituto de Salud Carlos III · ESInstitut Pasteur de Montevideo · UY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we have used bioinformatics tools to predict five clusters defining ligand-binding sites on the extracellular domain of human CD300b receptor, presumably involved in the formation of both homodimers and heterodimers with other CD300 family members. Site-directed mutagenesis revealed residues glutamic acid 28 and glutamine 29 in cluster 5 to be necessary for the formation of CD300b complexes. Surprisingly, the disruption of cluster 2 and 4 reconstituted the binding capability lost by the mutation of residues glutamic acid 28 to alanine, glutamine 29 to alanine (E28A-Q29G). We identified a missense mutation arginine 33 to glutamine (R33Q) in CD300f by direct sequencing of exon 2 in peripheral blood samples from 50 patients with multiple sclerosis (MS). Levels of expression of CD300f were almost undetectable on monocytes from the patient bearing the R33Q mutation compared with healthy individuals. Whereas R33Q mutation had no effect in the formation of CD300f complexes, the inhibition of protein synthesis with cycloheximide indicated that CD300f R33Q is less stable than native CD300f. Finally, we report that the levels of expression of CD300f on the surface of classical and intermediate monocytes from MS patients are significantly lower when compared to the same cell populations in healthy individuals.

Indexed as

AdultAmino Acid SequenceAnimalsBinding SitesCase-Control StudiesChlorocebus aethiopsCOS CellsCycloheximideFemaleGene ExpressionHumansLigandsMaleMonocytesMultiple SclerosisMutagenesis, Site-DirectedCD300LB protein, humanCD300LF protein, humanCycloheximideLigandsReceptors, Immunologic

Identifiers

PMID29051512
PMCPMC5648872
OpenAlexW2761886262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.